25 February 2020

The Blue Diamond Gallery

In line with the NFU initiative “Broad Consent at the Gate” (Breed Consent aan de Poort), the Radboud Biobank is currently conducting a feasibility study examining consent procedures for the use of residual material for scientific research. Residual material encompasses biomaterials leftover from standard clinical procedures, clinical imaging and medical data. The specific aim of this study is to evaluate the impact of implementing an active consent procedure (i.e. opt-in consent, which requires explicit consent) in place of the passive consent procedure currently used in the Radboudumc (i.e. opt-out consent, which requires explicit objection). Importantly, this study does not override the consent status of previously established research studies.
As of January 13, 2020, each new patient registering for the first time at the Radboudumc is actively asked for consent to use his/her residual biomaterial, clinical imaging and medical data for scientific research. To date, there has been no major organizational obstacles in the implementation of this new consent procedure. However, its impact on available material and data is still under evaluation. In addition to quantitative analyses, qualitative research exploring underlying motivations of patients who consent or do not consent to the use of their material and data will also be performed. This feasibility study will be further expanded to assess the impact of the new consent procedure on vulnerable patient groups, i.e. children (<16 years old), acute care patients, and incapacitated patients.   
For further information, please visit our website, “Use of medical data and leftover biomaterial”  (available in Dutch only), or contact Dr. Jennifer Lutomski, project leader, at Jennifer.Lutomski@radboudumc.nl.
 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud biobank

Related news items


First implications of the Radboud Biobank new business model

15 July 2025

It was communicated in an earlier news item that the Radboudumc Board of Directors decided to change the Radboud Biobank business model.

read more

Relocation of Radboud Biobank samples to Central Freezing Facility

15 July 2025

The Radboud Biobank has now transferred almost all stored samples to the central freezing facility.

read more

Standardized Radboud Biobank procedures for sample handling in Elabgids

15 July 2025

The Radboud Biobank is currently preparing to include all standardized Radboud Biobank procedures for sample handling in the eLabgids.

read more

Temporary new location Radboud Biobank Office

15 July 2025

The Radboud Biobank office has moved to a temporary new location: route 832 - M325.04.255 (building F).

read more

Europe Biobank Week 2025

15 July 2025

The Europe Biobank Week 2025 was a great success for the Dutch biobank community with a strong presence of Dutch biobanking and biomedical research.

read more

National Biobanks & Collections Dag 2025

6 May 2025

The second edition of the National Biobanks & Collections Day took place on March 27, 2025, in Nijmegen and attracted 150 participants from all over the Netherlands.

read more